The biotech industry giant,
Revvity Inc, has been under intense scrutiny amid funding concerns, leading to lowered price targets, from $140 to $120 by
Bernstein, and from $143 to $116 by
BofA. Despite this, the company has reported robust growth, surpassing Q4 earnings estimates, and even declared quarterly dividends. Revvity has also experienced strong organic growth and reiterated its commitment to transforming neonatal genetic testing through strategic partnerships. The company ´s new FDA-approved TB testing system has been a groundbreaking achievement, reducing testing time by 70%. Revvity, however, predicts lower 2025 earnings despite strong fourth quarter. In terms of investments, several financial institutions and independent investors have seen fluctuations in their holdings in Revvity. It is unclear how these institutional changes will affect the company's stock value. Despite ups and downs, some believe Revvity still holds favorable investment prospects due to its innovations in the diagnostics sector. They've demonstrated their commitment to this with their automated TB and newborn genetic screening tests.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Sat, 19 Apr 2025 08:06:50 GMT -
Rating -2
- Innovation 6
- Information 8
- Rumor 2
